SOCS-2 mRNA expression in patients with CML in BC responding to STI571 therapy.

Northern blots of RNA from 5 patients with CML in myeloid BC before and during STI571 therapy, probed with SOCS-2 andβ-actin. The numbers below the blots refer to the densitometric calculation of SOCS-2 levels, normalized toβ-actin. For interindividual comparison of samples, levels before therapy were defined as being 1, and levels under therapy were compared with that value.